title: Factors associated with the response of age-related macular degeneration to intravitreal ranibizumab treatment.
abstract: OBJECTIVE
  To investigate factors affecting patient response to intravitreal ranibizumab treatment for age-related macular degeneration (AMD).
  
  
  METHODS
  Retrospective chart review.
  
  
  METHODS
  We reviewed medical records of 105 consecutive eyes with AMD treated with intravitreal ranibizumab injections and followed for more than 1 year after treatment. Response to ranibizumab treatment was compared between typical neovascular AMD and polypoidal choroidal vasculopathy (PCV). Furthermore, we investigated associations of age, lesion size, and single nucleotide polymorphisms (SNPs) in CFH and ARMS2 genes with treatment response.
  
  
  RESULTS
  Forty-nine eyes were diagnosed with typical neovascular AMD and 56 eyes with PCV. Serous retinal detachment and retinal edema resolved similarly in both typical neovascular AMD and PCV after treatment. However, visual acuity (VA) significantly improved in eyes with PCV, whereas VA was maintained in typical neovascular AMD. At the third and twelfth months after injection, VA was better in PCV than in typical neovascular AMD (P = .027 and P = .044, respectively), although there were no differences in baseline VA between the 2 groups. Age and size of greatest linear dimension were significantly associated with visual prognosis in typical neovascular AMD but not in PCV. There was no clear association between 3 SNPs and responsiveness to ranibizumab treatment.
  
  
  CONCLUSIONS
  Although exudative changes were equivalent following ranibizumab treatment in both typical neovascular AMD and PCV, there was a significant increase in VA in PCV compared to typical neovascular AMD. Age and greatest linear dimension correlated with visual prognosis only in typical neovascular AMD and not in PCV.
authors.affiliation: Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan. yamashro@kuhp.kyoto-u.ac.jp
authors.forename: Kenji
authors.initials: K
authors.lastname: Yamashiro
authors.forename: Kaoruko
authors.initials: K
authors.lastname: Tomita
authors.forename: Akitaka
authors.initials: A
authors.lastname: Tsujikawa
authors.forename: Isao
authors.initials: I
authors.lastname: Nakata
authors.forename: Yumiko
authors.initials: Y
authors.lastname: Akagi-Kurashige
authors.forename: Masahiro
authors.initials: M
authors.lastname: Miyake
authors.forename: Sotaro
authors.initials: S
authors.lastname: Ooto
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Tamura
authors.forename: Nagahisa
authors.initials: N
authors.lastname: Yoshimura
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D015862:Choroid Diseases / Q000188:drug therapy / Q000235:genetics; D004396:Coloring Agents; D017242:Complement Factor H / Q000235:genetics; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D005838:Genotype; D006801:Humans; D007208:Indocyanine Green; D058449:Intravitreal Injections; D008297:Male; D016491:Peripheral Vascular Diseases / Q000188:drug therapy / Q000235:genetics; D020641:Polymorphism, Single Nucleotide; D011127:Polyps / Q000188:drug therapy / Q000235:genetics; D011506:Proteins / Q000235:genetics; D000069579:Ranibizumab; D012189:Retrospective Studies; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000502:physiology; D057135:Wet Macular Degeneration / Q000188:drug therapy* / Q000235:genetics
chemical_list: C514392:ARMS2 protein, human; D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; C493495:CFH protein, human; D004396:Coloring Agents; D011506:Proteins; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D017242:Complement Factor H; D007208:Indocyanine Green; D000069579:Ranibizumab